Inhibikase Therapeutics (IKT) Revenue & Revenue Breakdown
Inhibikase Therapeutics Revenue Highlights
Latest Revenue (Y)
$260.50K
Inhibikase Therapeutics Revenue by Period
Inhibikase Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $260.50K | 111.03% |
| 2022-12-31 | $123.44K | -96.02% |
| 2021-12-31 | $3.10M | 343.92% |
| 2020-12-31 | $698.47K | -37.79% |
| 2019-12-31 | $1.12M | -72.22% |
| 2018-12-31 | $4.04M | - |
Inhibikase Therapeutics generated $260.50K in revenue during NA 2023, up 111.03% compared to the previous quarter, and up 6.45% compared to the same period a year ago.
Inhibikase Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $1.00 | -100.00% |
| 2023-09-30 | $79.57K | -31.65% |
| 2023-06-30 | $116.41K | 80.42% |
| 2023-03-31 | $64.52K | -47.73% |
| 2022-12-31 | $123.44K | 1593.05% |
| 2022-09-30 | $7.29K | 11.28% |
| 2022-06-30 | $6.55K | -85.77% |
| 2022-03-31 | $46.03K | 2267.85% |
| 2021-12-31 | $1.94K | -99.41% |
| 2021-09-30 | $328.46K | -75.90% |
| 2021-06-30 | $1.36M | -3.14% |
| 2021-03-31 | $1.41M | 101.46% |
| 2020-12-31 | $698.47K | 1753.68% |
| 2020-09-30 | $37.68K | -82.84% |
| 2020-06-30 | $219.59K | -18.91% |
| 2020-03-31 | $270.79K | 12.70% |
| 2019-12-31 | $240.28K | 93.10% |
| 2019-09-30 | $124.43K | -25.46% |
| 2019-06-30 | $166.93K | -71.76% |
| 2019-03-31 | $591.10K | -14.48% |
| 2018-03-31 | $691.20K | 179.41% |
| 2017-03-31 | $247.38K | - |
Inhibikase Therapeutics generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Inhibikase Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MCRB | Seres Therapeutics | $126.33M | - |
| SCPH | scPharmaceuticals | $13.59M | $6.10M |
| NTRB | Nutriband | $2.09M | $442.83K |
| MIST | Milestone Pharmaceuticals | $1.00M | - |
| LGVN | Longeveron | $709.00K | $548.00K |
| LIFE | aTyr Pharma | $353.00K | $235.00K |
| IKT | Inhibikase Therapeutics | $260.50K | - |
| VRAX | Virax Biolabs Group | $8.56K | $76.50K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| ANTX | AN2 Therapeutics | - | - |
| DMAC | DiaMedica Therapeutics | - | - |
| RNXT | RenovoRx | - | - |
| TPST | Tempest Therapeutics | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| ONCY | Oncolytics Biotech | - | - |
| SIOX | Sio Gene Therapies | - | - |
| QNRX | Quoin Pharmaceuticals | - | - |
IKT Revenue FAQ
What is Inhibikase Therapeutics’s yearly revenue?
Inhibikase Therapeutics's yearly revenue for 2023 was $260.5K, representing an increase of 111.03% compared to 2022. The company's yearly revenue for 2022 was $123.44K, representing a decrease of -96.02% compared to 2021. IKT's yearly revenue for 2021 was $3.1M, representing an increase of 343.92% compared to 2020.
What is Inhibikase Therapeutics’s quarterly revenue?
Inhibikase Therapeutics's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a -100.00% decrease year-over-year (Q1 2023). IKT's quarterly revenue for Q4 2023 was $1, a -100.00% decrease from the previous quarter (Q3 2023), and a -100.00% decrease year-over-year (Q4 2022).
What is Inhibikase Therapeutics’s revenue growth rate?
Inhibikase Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -91.60%, and for the last 5 years (2019-2023) was -76.80%.